Prelude Therapeutics Inc (PRLD)
4.10
-0.02
(-0.49%)
USD |
NASDAQ |
May 21, 16:00
4.10
0.00 (0.00%)
After-Hours: 18:12
Prelude Therapeutics Enterprise Value: 24.39M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 24.39M |
| May 17, 2024 | 17.79M |
| May 16, 2024 | 33.17M |
| May 15, 2024 | 17.79M |
| May 14, 2024 | 10.10M |
| May 13, 2024 | 6.808M |
| May 10, 2024 | 2.963M |
| May 09, 2024 | 21.64M |
| May 08, 2024 | -4.727M |
| May 07, 2024 | 1.316M |
| May 06, 2024 | 8.456M |
| May 03, 2024 | 10.10M |
| May 02, 2024 | 17.25M |
| May 01, 2024 | 2.963M |
| April 30, 2024 | 5.161M |
| April 29, 2024 | 9.006M |
| April 26, 2024 | 21.64M |
| April 25, 2024 | 19.99M |
| April 24, 2024 | 10.65M |
| April 23, 2024 | 10.65M |
| April 22, 2024 | 9.555M |
| April 19, 2024 | 2.414M |
| April 18, 2024 | -12.97M |
| April 17, 2024 | 27.65M |
| April 16, 2024 | 67.74M |
| Date | Value |
|---|---|
| April 15, 2024 | 107.29M |
| April 12, 2024 | 106.74M |
| April 11, 2024 | 84.77M |
| April 10, 2024 | 69.94M |
| April 09, 2024 | 72.14M |
| April 08, 2024 | 56.21M |
| April 05, 2024 | 56.21M |
| April 04, 2024 | 58.41M |
| April 03, 2024 | 57.31M |
| April 02, 2024 | 51.81M |
| April 01, 2024 | 55.66M |
| March 28, 2024 | 27.39M |
| March 27, 2024 | 29.04M |
| March 26, 2024 | 20.25M |
| March 25, 2024 | 20.25M |
| March 22, 2024 | 25.19M |
| March 21, 2024 | 31.78M |
| March 20, 2024 | 32.88M |
| March 19, 2024 | 32.88M |
| March 18, 2024 | 22.45M |
| March 15, 2024 | 27.39M |
| March 14, 2024 | 12.01M |
| March 13, 2024 | 20.80M |
| March 12, 2024 | -7.760M |
| March 11, 2024 | -8.310M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-137.85M
Minimum
Oct 31 2023
4.052B
Maximum
Feb 10 2021
558.99M
Average
112.99M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 62.93M |
| AIM ImmunoTech Inc | 13.60M |
| IGC Pharma Inc | 33.12M |
| NovaBay Pharmaceuticals Inc | 7.267M |
| Protalix BioTherapeutics Inc | 59.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.43M |
| Total Expenses (Quarterly) | 34.34M |
| EPS Diluted (Quarterly) | -0.42 |
| Earnings Yield | -45.85% |